GW Pharmaceuticals has received the Queen’s Award for Enterprise 2021 in the Innovation category, recognising the company’s work to harness cannabinoid science to create the world’s first regulatory approved, prescription cannabis-based medicines.
Since its inception in 1998, GW worked on the development, manufacture and commercialisation of regulatory approved cannabis-based medicines. Globally, GW has invested more than £1.3 billion in the research, development and infrastructure needed to bring medicines to patients.
Dr Geoffrey Guy, GW Founder and Chairman, said: “Much of what is known about the medical uses of cannabis was discovered by GW. We have led the way in understanding cannabinoid science and how, if harnessed correctly and taken through the regulatory approval pathway, it has the potential to improve the lives of patients and their families.”
